US Flagship Manufacturing and Clinical R&D Center Breaks Ground in New Jersey for BeiGene

New Jersey Governor Phil Murphy; Hopewell Mayor Courtney Peters-Manning; John V. Oyler, Co-Founder, Chairman, and CEO of BeiGene; DPR Construction, IPS, and distinguished guests broke ground on BeiGene’s new manufacturing and clinical R&D center at the Princeton West Innovation Campus. The new innovation hub will focus on developing affordable medicines to improve cancer treatment outcomes. The initial phase of construction includes approximately 400,000-sq.-ft. of biologic pharmaceutical manufacturing space.

State and local officials, executives from BeiGene, and the design and construction teams celebrate
State and local officials, executives from BeiGene, and the design and construction teams celebrate the momentous occasionduring the groundbreaking ceremony. Courtesy of Russ DeSantis Photography and Video

“At BeiGene, we are committed to not only delivering innovative and affordable medicines but also to upholding the highest standards of ethics and integrity, operational excellence, and environmental stewardship,” stated John V. Oyler, Co-Founder, Chairman and CEO of BeiGene.“This commitment applies to everything we do, including the development of BeiGene’s Hopewell project.

Rendering of the BeiGene building. This is the exterior view of what the building will look like.
BeiGene’s flagship US facility will support state-of-the-art commercial-stage biologic pharmaceutical manufacturing, late-stage research, and clinical development. Courtesy of IPS

Through persistent innovation and challenging the status quo, IPS and our design partners, Van Note-Harvey Associates, Meyer Design, and Mainstay Engineering have worked interactively in developing a comprehensive execution approach focused on value to bring the Princeton West Campus project to reality. Additionally, DPR is self-performing select scopes of work. Leveraging our own forces helps alleviate workforce demands and the labor shortage across the AEC industry.

“We are providing counsel on design partners and consultants, phasing options for construction, and the equipment needed to build an immunotherapy facility in the US,” noted DPR’s Frank Haughey, Project Executive. “The Mid-Atlantic region of the US is a hotspot for pharmaceutical research and manufacturing, and BeiGene will have access to a deep talent pool and thriving business community to support their operation and future growth.”

We think you'll like this, too.